AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Nacionale

Published November 4, 2026 · Updated November 5, 2026

Does psilocybin have lasting effects? Five labs ran the same mouse tests and found little

Read the full story at Nacionale

psychedelic response. They ... UCSF's Vikaas Sohal warned of a risk “if the hype around psychedelics outruns the science”, Berkeley reported.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelics